Paeds SAQs · genetics-dysmorphology-and-metabolism
Fatty-acid oxidation disorders — formative SAQs
Formative SAQs on recognising the hypoketotic hypoglycaemia signature of a fatty-acid oxidation disorder, delivering the acute intravenous-dextrose protocol, localising the defect with plasma acylcarnitines, and locking in long-term fasting avoidance, an emergency sick-day plan, and disease-specific therapy for long-chain defects.
On this page
Study tools
Target exams
SAQ 1 (10 marks)
A 14-month-old girl is brought to the emergency department with a two-day history of vomiting and lethargy following a febrile illness. She has not eaten for approximately 14 hours. On arrival she is drowsy, her bedside glucose is 1.8 mmol/L, and a point-of-care ketone measurement returns 0.1 mmol/L. [1] [5]
a) Explain why the combination of a low blood glucose with inappropriately low ketones is the signature of a fatty-acid oxidation disorder, and describe the physiological mechanism that produces this pattern. (3 marks) [1] [5]
b) Outline the immediate resuscitation you perform, including the specific intravenous therapy and why glucagon would be ineffective. (3 marks) [1] [2]
c) Describe the critical sample you collect at the time of hypoglycaemia and the first-tier diagnostic test that will localise the defect. Explain how plasma acylcarnitines would distinguish MCAD deficiency from a long-chain defect. (2 marks) [1]
d) Discuss the long-term management plan, including fasting avoidance, the emergency sick-day plan, and how newborn screening changed the prognosis of this condition. (2 marks) [5] [7]
References6ShowHide
- [1]Merritt JL 2nd, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med, 2018.PMID 30740404
- [2]Vockley J Long-chain fatty acid oxidation disorders and current management strategies. Am J Manag Care, 2020.PMID 32840329
- [5]Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis, 2010.PMID 20049534
- [6]Derks TG, Reijngoud DJ, Waterham HR, et al. The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: clinical presentation and outcome. J Pediatr, 2006.PMID 16737882
- [7]Wilcken B, Haas M, Joy P, Wiley V, et al. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics, 2009.PMID 19620191
- [9]Vockley J, Burton B, Berry GT, Longo N, et al. Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study. J Inherit Metab Dis, 2023.PMID 37276053